№ lp_1_2_22723
File format: docx
Character count: 14782
File size: 47 KB
Discussion on the potential broad listing of PD-(L)1 inhibitors for non-small cell lung cancer (NSCLC) under the Pharmaceutical Benefits Scheme (PBS) in Australia, including stakeholder input and recommendations.
Year:
2019
Region / City:
Australia
Topic:
Pharmaceutical Benefits Scheme, PD-(L)1 inhibitors, non-small cell lung cancer (NSCLC)
Document type:
Meeting minutes
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Professor Andrew Wilson (PBAC Chair)
Target audience:
Stakeholders in the healthcare and pharmaceutical industry
Period of validity:
2019 and onwards
Date of approval:
February 2019
Date of amendments:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Document Type:
Supplementary appendix
Subject Area:
Oncology
Disease Focus:
Renal cell carcinoma
Content Type:
Tables and figures
Population:
Patients with renal cell carcinoma
Sample Size:
43 patients (baseline characteristics), 19 patients (tumor mutation burden), 8 patients (PD-L1 expression)
Variables:
Age, sex, ECOG performance status, histology, sarcomatoid/rhabdoid differentiation, IMDC risk group, metastases, prior nephrectomy, therapy line
Biomarkers:
Tumor mutation burden, PD-L1 expression
Outcomes:
Best overall response, overall survival
Response Categories:
Partial response, stable disease, progressive disease
Institutions Referenced:
Eastern Cooperative Oncology Group, International Metastatic RCC Database Consortium
Language:
English
Data Presentation:
Quantitative tabular data with percentages and counts
Year:
2022
Region / City:
Daejeon, Republic of Korea
Subject:
Pharmacology, Immunotherapy, Herbal Medicine
Document Type:
Supplementary Research Document
Institution:
Chungnam National University, Korea Institute of Oriental Medicine
Authors:
Sung-yoon Yang, Jin-Mu Yi, Jaemoo Chun, Seongwon Park, Tham Thi Bui, Hwi-yeol Yun, Jung-woo Chae, Mi-Kyung Jeong
Target Audience:
Researchers in pharmacology and immunotherapy
Methodologies:
LC-MS/MS, ELISA, Cytokine Assay
Compounds Analyzed:
Bojungikki-tang components, anti-PD-L1 antibody
Study Model:
Mouse serum samples
Purpose:
Assessment of pharmacokinetic interactions and biomarker quantification
Year:
2023
Region / City:
Australia
Subject:
Health / Oncology
Document Type:
Official Announcement
Organization:
Department of Health and Aged Care
Author:
Medical Services Advisory Committee (MSAC), Pharmaceutical Benefits Advisory Committee (PBAC)
Target Audience:
Healthcare providers, specialists
Effective Date:
1 September 2023
Approval Date:
10 August 2023
Changes Date:
1 September 2023
Clinical Category:
Pathology Services
Procedure Type:
Type C
Private Health Insurance Classification:
Support List (pathology)
MBS Item:
72814
PBS Listing:
pembrolizumab (Keytruda®)
Eligibility Criteria:
Advanced TNBC, PD-L1 Combined Positive Score (CPS) ≥10
Consulted Stakeholders:
Clinical experts, providers, consumer health representatives
Review and Monitoring:
Compliance audits
More Information:
www.mbsonline.gov.au
Description:
Official update on the inclusion of PD-L1 immunohistochemistry testing for advanced triple negative breast cancer (TNBC) patients under the Medicare Benefits Schedule (MBS) effective 1 September 2023, aligned with PBS listing for pembrolizumab.
Year:
2026
Region/Location:
Not specified
Subject:
Melanoma research
Document type:
Supplementary data tables
Institution:
Research laboratory / academic study
Author:
Not specified
Sample size:
NEVI (14), Primary Malignant Melanoma (23), Metastatic Melanoma (15)
Methods:
Immunohistochemistry for PD-L1, BRAF codon 600 genotyping, inflammatory scoring
Cell lines:
Human melanoma cultured cells
Treatment:
IFN-gamma induction
Data metrics:
%PD-L1 expression, inflammation score, ∆MFI for PD-L1 and MHC I
Context:
Archival melanoma tissue samples and cultured melanoma cell lines analyzed for PD-L1 expression, BRAF mutation status, and immune response markers in experimental study
Year:
2018
Region:
Australia
Subject:
PD-1 and PD-L1 checkpoint inhibitor immunotherapies
Document Type:
Submission Template
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Intended Audience:
Patients, healthcare providers, researchers, pharmaceutical industry, government bodies
Submission Deadline:
29 June 2018
Contact Information Required:
Yes
Confidentiality Note:
Commercial-in-confidence or personal information to be redacted before publication
Format:
Electronic submission in Microsoft Word or text-based format
Questions Covered:
Advantages, disadvantages, unmet clinical need, evidence requirements, cost-effectiveness, subsidy pricing, biomarker considerations, extrapolation across medicines and cancer types, rare cancers, follow-up actions, clinical trials, international models
Year:
2026
Region / City:
Not specified
Subject:
Oncology, Immunology
Document type:
Supplementary Figure
Institution:
Not specified
Authors:
Not specified
Target audience:
Researchers, Clinicians
Study focus:
CD8 densities and PD-L1 expression in small cell and esophageal carcinomas
Data type:
Quantitative immunohistochemical analysis
Tumor types:
Small cell lung carcinoma, small cell carcinoma of the prostate, small cell carcinoma of the bladder, small cell carcinoma of the esophagus, esophageal squamous cell carcinoma, esophageal adenocarcinoma
Measurement methods:
Immunohistochemistry, Tumor-infiltrating immune cells analysis
Year:
2026
Region / city:
Canadian Ski Marathon
Theme:
Checkpoint operations, volunteer duties, and event coordination
Document type:
Manual
Organization / institution:
Canadian Ski Marathon
Author:
CSM Event Director, CSM Admin-2
Target audience:
Event leaders, checkpoint/task leaders, volunteers
Period of validity:
February 6-8, 2026
Approval date:
N/A
Modification date:
N/A
Year:
2023
Region / City:
Wuhan, China
Topic:
Immunology, Cancer Research, Gene Expression, Immunotherapy
Document Type:
Research Article
Institution:
Wuhan University of Science & Technology, Huazhong University of Science and Technology, Anhui Normal University
Authors:
Fei-Fei Hu, Chun-Jie Liu, Lan-Lan Liu, Qiong Zhang, An-Yuan Guo
Target Audience:
Researchers, Healthcare Professionals, Academics in Immunology and Oncology
Period of Validity:
N/A
Approval Date:
N/A
Date of Last Revision:
N/A
Year:
2026
Region / City:
N/A
Theme:
American Sign Language Assessment
Document Type:
Examination
Institution:
N/A
Author:
N/A
Target Audience:
Students of American Sign Language
Validity Period:
N/A
Approval Date:
June 22, 2026
Modification Date:
N/A
Date:
June 24, 2025
Region / City:
Hemet, California, United States
Topic:
Road safety and impaired driving enforcement
Document Type:
Press release / public safety announcement
Organization:
Hemet Police Department
Prepared by:
Sergeant M. Chavez
Contact Person:
Sergeant Matt Chavez
Contact Phone:
(951) 765-2400
Contact Email:
[email protected]
Media Contact:
Public Information Social Media Officer Judith Gibson
Media Contact Email:
[email protected]
Event Date:
July 11, 2025
Event Time:
8:00 pm – 2:00 am
Event Type:
DUI and Driver’s License Checkpoint
Location:
Undisclosed location within the City of Hemet
Funding Source:
California Office of Traffic Safety grant through the National Highway Traffic Safety Administration
Target Audience:
Drivers and residents of the City of Hemet
Subject Details:
Enforcement of laws related to driving under the influence of alcohol, drugs, prescription medication, and marijuana
Year:
2018
Region:
Australia
Subject:
PD-1 and PD-L1 checkpoint inhibitor immunotherapies
Document Type:
Submission Template
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Intended Audience:
Patients, healthcare providers, researchers, pharmaceutical industry, government bodies
Submission Deadline:
29 June 2018
Contact Information Required:
Yes
Confidentiality Note:
Commercial-in-confidence or personal information to be redacted before publication
Format:
Electronic submission in Microsoft Word or text-based format
Questions Covered:
Advantages, disadvantages, unmet clinical need, evidence requirements, cost-effectiveness, subsidy pricing, biomarker considerations, extrapolation across medicines and cancer types, rare cancers, follow-up actions, clinical trials, international models
Year:
2019–2024
Region:
International
Topic:
Oncology / Hepatocellular Carcinoma
Document Type:
Meta-analysis
Institution:
Multiple clinical research centers
Authors:
Various (from included RCTs)
Target Audience:
Medical researchers, oncologists, clinicians
Study Design:
Randomized controlled trials, Phase II and III
Interventions:
Nivolumab, Pembrolizumab, Atezolizumab, Sintilimab
Comparators:
Placebo, standard care, active surveillance
Outcomes Measured:
Overall survival (OS), Recurrence-free survival (RFS), adverse events (AEs)
Sample Size:
Data pooled from 10 studies
Statistical Methods:
DerSimonian-Laird random-effects model, hazard ratios (HRs), risk ratios (RRs)
Adverse Events Reported:
Fatigue, hypertension, elevated liver enzymes (grade 3+)
Publication Type:
Peer-reviewed articles
Description:
Systematic review and meta-analysis of clinical trials assessing survival outcomes and safety of adjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma after curative treatment.
Year:
2021
Region / city:
Not specified
Topic:
Resource multiplexing between child and parent links of IAB node
Document type:
Contribution
Organization:
3GPP TSG RAN WG1
Author:
Moderator (AT&T)
Target audience:
3GPP members, stakeholders in telecommunications standards
Period of validity:
January 25th – February 5th, 2021
Approval date:
Not specified
Amendment date:
Not specified
Summary:
This document provides a summary of various proposals for improving resource multiplexing between the child and parent links of an IAB node, particularly focused on simultaneous operations, frequency domain multiplexing, and operational resource configurations.
Year:
2021
Organization:
3GPP TSG RAN WG1
Document type:
Technical contribution
Source:
Moderator (AT&T)
Title:
Summary of [104-e-NR-eIAB-01] – 1st Checkpoint
Agenda item:
8.10.1
Scope:
Enhancements to resource multiplexing between child and parent links of an IAB node
Contributors:
Huawei, Vivo, Intel, CEWiT, IITM, IITH, Tejas Networks, Reliance Jio
Target audience:
RAN working group members
Checkpoint dates:
Jan 27, Feb 5, Feb 13
Topics covered:
Simultaneous operation of access and backhaul links, dual-connectivity, TDD configurations, resource allocation strategies
Year:
2014
Software Version:
vCO 5.5.2, vRO HTTP REST Plugin 1.0.7
Region:
Global
Document Type:
Installation and Configuration Guide
Author:
VMware / CheckPoint
Target Audience:
System administrators, IT engineers
Required Environment:
vCenter 5.5.0, Windows client for vCO, CheckPoint Management Server
Procedures Included:
OVF deployment, password setup, network configuration, SSL certificate import, SSO authentication, plugin installation, workflow execution
Troubleshooting Notes:
Password issues, SSL key errors, time synchronization
Workflow Examples:
Add Host, Add Host to Group, Add Access Rule, Install Policy
Year:
2021
Region / city:
N/A
Document type:
Research supplementary materials
Organization / institution:
University of North Carolina
Author:
Ling Xie, Ryan N. Sheehy, Yan Xiong, Adil Muneer, John A. Wrobel, Kwang-Su Park, Julia Velez, Jing Liu, Yan-Jia Luo, Ya-Dong Li, Luis Quintanilla, Yongyi Li, Chongchong Xu, Mohanish Deshmukh, Zhexing Wen, Jian Jin, Juan Song, Xian Chen
Target audience:
Researchers in neuroscience, pharmacology, and precision medicine
Period of validity:
N/A
Approval date:
N/A
Date of amendments:
N/A
Year:
2013
Region / City:
Leeds, Yorkshire and The Humber
Theme:
Clinical trials, Chronic Kidney Disease
Document type:
Research study protocol
Organization:
University of Birmingham Clinical Trials Unit, Hull and East Yorkshire Hospitals NHS Trust
Author:
Prof Sunil Bhandari
Target audience:
Healthcare professionals, nephrologists, researchers
Period of validity:
3 years
Approval date:
2013
Change date:
N/A
Study reference number:
11/30/07
Ethics committee reference:
13/YH/0394
EudraCT number:
2013-003798-82
Sponsor:
Hull and East Yorkshire Hospitals NHS Trust
Funding source:
Efficacy and Mechanism Evaluation (EME) programme, National Institute for Health Research (NIHR), Medical Research Council (MRC)
Note:
Contextual description
Year:
2026
Region / City:
Global
Topic:
Pharmacogenetics, Antidepressants
Document Type:
Guideline
Organization / Institution:
Clinical Pharmacogenetics Implementation Consortium (CPIC)
Authors:
Chad A. Bousman, James M. Stevenson, Laura B. Ramsey, Katrin Sangkuhl, J. Kevin Hicks, Jeffrey R. Strawn, Ajeet B. Singh, Gualberto Ruaño, Daniel J. Mueller, Evangelia Eirini Tsermpini, Jacob T. Brown, Gillian C. Bell, J. Steven Leeder, Andrea Gaedigk, Stuart A. Scott, Teri E. Klein, Kelly E. Caudle, Jeffrey R. Bishop
Target Audience:
Healthcare professionals, geneticists, pharmacologists
Effective Period:
Ongoing
Approval Date:
2026
Modification Date:
Not specified
Year:
2026
Region / City:
Southampton, U.K.; Newcastle upon Tyne, U.K.; Cambridge, U.K.
Subject:
Biochemistry, Cancer Research
Document Type:
Research Article
Organization / Institution:
University of Southampton, Newcastle University, AstraZeneca
Author:
Eliot L. Osher, Francisco Castillo, Nagarajan Elumalai, Michael J. Waring, Garry Pairaudeau, Ali Tavassoli
Target Audience:
Researchers, Scientists, Medical Professionals
Duration:
Ongoing
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2023
Region / City:
Global
Topic:
Research
Document Type:
Technical Data Sheet
Organization / Institution:
Abcam
Author:
Abcam
Target Audience:
Researchers, Laboratory Technicians
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Description:
Technical data sheet detailing the usage and protocol for the COX2 Inhibitor Screening Kit (Fluorometric), a product intended for high-throughput screening of COX-2 inhibitors in research laboratories.